MDGL
Madrigal Pharmaceuticals Inc
NASDAQ: MDGL · HEALTHCARE · BIOTECHNOLOGY
$518.58
+0.37% today
Updated 2026-04-29
Market cap
$11.96B
P/E ratio
—
P/S ratio
12.48x
EPS (TTM)
$-12.87
Dividend yield
—
52W range
$265 – $615
Volume
0.4M
Madrigal Pharmaceuticals Inc (MDGL) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-30.10%
Operating margin
-18.60%
ROE
-42.50%
ROA
-16.30%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | — | $-57.27M | — | — | — |
| 2007 | $743000.00 | $-63.49M | 100.00% | -8,911.98% | -8,545.76% |
| 2008 | $2.62M | $-92.62M | 100.00% | -3,583.48% | -3,541.80% |
| 2009 | $144.25M | $79.09M | 100.00% | 55.84% | 54.83% |
| 2010 | $14.80M | $-37.47M | 100.00% | -249.26% | -253.10% |
| 2011 | $7.58M | $-47.38M | 80.70% | -599.05% | -624.74% |
| 2012 | $147000.00 | $-62.79M | -502.04% | -41,556.46% | -42,714.29% |
| 2013 | $0.00 | $-90.19M | — | — | — |
| 2014 | $0.00 | $-86.16M | — | — | — |
| 2015 | $0.00 | $-6.84M | — | — | — |
| 2016 | $0.00 | $-26.39M | — | — | — |
| 2017 | $350000.00 | $-31.15M | 100.00% | -9,160.57% | -8,901.14% |
| 2018 | $200000.00 | $-32.81M | 100.00% | -20,341.00% | -16,405.50% |
| 2019 | $0.00 | $-72.81M | — | — | — |
| 2020 | $21864.00 | $-197.44M | 100.00% | -945,266.19% | -903,055.25% |
| 2021 | $37318.00 | $-241.08M | 731.55% | -649,772.23% | -646,009.97% |
| 2022 | $0.00 | $-295.35M | — | — | — |
| 2023 | $0.00 | $-373.63M | — | — | — |
| 2024 | $180.13M | $-465.89M | 96.54% | -276.39% | -258.64% |
| 2025 | $958.40M | $-288.28M | 94.14% | -31.31% | -30.08% |